Webinar: The Endocannabinoid System and Non-Cannabis Compounds in Clinical Practice: Palmitoylethanolamide (PEA) and Beta-Caryophyllene, October 7, 2020

SKU
26WEB1CS2020
Complimentary
APPLY FOR AN ACCOUNT TO REGISTER

The Endocannabinoid System and Non-Cannabis Compounds in Clinical Practice: Palmitoylethanolamide (PEA) and Beta-Caryophyllene
Wednesday, October 7, 2020

Palmitoylethanolamide (PEA), an endogenous fatty acid amide, is clearly emerging as a new agent in the therapeutic support of patients. PEA has been shown to have a supportive effect on pain management. This endogenous agent, which is also found in foods, has been used for decades in the Netherlands and other parts of Europe, and has now made its way to North America.

Key highlights:
  • The role of the endocannabinoid system (ECS), receptors, the mechanism of action of endocannabinoids, and endocannabinoid tone
  • The concept of the “entourage effect” and an introduction to synergistic compounds including the terpenes, beta-caryophyllene and the long-chain fatty acid palmitoylethanolamide
  • Clinical evidence for PEA (palmitoylethanolamide) and beta-caryophyllene (BCP)
  • Accessory pathways that can be targeted for integrative approaches to support endocannabinoid tone

A .pdf file will be emailed prior to the live webinar.